Finanzen von Eton Pharmaceuticals Inc (ETON)ETONEton Pharmaceuticals Inc

Evaluating the bottom line, Eton Pharmaceuticals Inc maintains a gross margin of 67.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 34.04%, while the net margin is 30.80%. These profitability ratios, combined with a Return on Equity (ROE) of 35.97%, provide a clear picture of how effectively ETON converts its operational activities into shareholder value.

In the context of the broader market, ETON competes directly with industry leaders such as OCUL and PCRX. With a market capitalization of $1.58B, it holds a significant position in the sector. When comparing efficiency, ETON's gross margin of 67.61% stands against OCUL's 85.08% and PCRX's 69.60%. Such benchmarking helps identify whether Eton Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eton has shown significant revenue growth, with Q2 2026 revenue reaching $37.59 million, and net income for the same quarter at $11.58 million, translating to a net margin of 30.80%.